Table 4.
The PK/PD target attainment in the course of therapy with meropenem of patients with or without fluid overload on day 1
| Characteristics | Day | Fluid overload | No fluid overload |
|---|---|---|---|
| f Cmin > 2 mg/L (%)a | 1–3 | 98 (89–100) | 93 (80–98) |
| f Cmin > 8 mg/L (%)a | 1–3 | 67 (52–80) | 27 (20–48)*** |
| %f T > 2 mg/L (%)b | 1 | 99 (2.3) | 99 (2.7) |
| 2 | 100 (0.1) | 98 (1.6) | |
| 3 | 99 (1.2) | 100 (0.1) | |
| %f T > 8 mg/L (%)b | 1 | 79 (17)#,3 | 58 (17)# |
| 2 | 78 (23)# | 56 (13)# | |
| 3 | 68 (21)#,1 | 58 (12)# |
a the point estimate (95-% confidence interval) of the percent proportion, b the mean (standard deviation), *** p < 0.001 Fisher's exact test.; the results of the Tukey–Kramer multiple-comparison test (α = 0.05): upper numbers indicate within-group differences between the monitoring days 1, 2 and 3; # the between-group difference at the particular day.; abbreviations: fCmin > MIC the proportion of the assayed minimum concentrations of meropenem exceeding the targets of 2 mg/L and 8 mg/L; %f T > MIC the fraction time on the days 1, 2 and 3 with the concentration of meropenem exceeding the targets of 2 mg/L and 8 mg/L